Aldosterone and antialdosterone therapy in congestive heart failure.
Aldosterone and antialdosterone therapy in congestive heart failure.
复制标题
醛固酮和抗醛固酮治疗充血性心力衰竭。
DOI：
10.1016/0002-9149(93)90238-8
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Villarreal,D
中科院分区：
文献类型：
--
作者：
Weber,KT;Villarreal,D
心肌衰竭与充血性心力衰竭之间的病理生理循环尚不完全清楚。然而，很明显，几种神经激素系统的激活以及肾脏、肾上腺和心脏之间的相互作用导致了异常的钠和水稳态。醛固酮是体内最有效的盐皮质激素，有助于血管内和血管外容量扩张，从而导致症状性衰竭的出现。对心力衰竭继发性醛固酮增多症患者的抗醛固酮治疗必须达到以下一个或多个目标：通过限制合成降低或最好使血浆醛固酮水平正常化;拮抗醛固酮在其受体部位的肾脏和全身作用;消除或最小化对醛固酮分泌的多种刺激。
The pathophysiologic cycle that links myocardial failure with the appearance of congestive heart failure is not fully understood. It is clear, however, that an activation of several neurohormonal systems and the interplay between kidneys, adrenal glands, and heart contribute to abnormal sodium and water homeostasis. Aldosterone, the body's most potent mineralocorticoid hormone, contributes to intravascular and extravascular volume expansion, and thus to the appearance of symptomatic failure. Antialdosterone therapy in patients with secondary hyperaldosteronism due to heart failure must achieve one or more of the following goals: reduce or, preferably, normalize plasma aldosterone levels by limiting synthesis; antagonize the renal and systemic effects of aldosterone at its receptor sites; and eliminate or minimize the multiple stimuli to aldosterone secretion.